A Population Pharmacokinetic and Exposure-Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis.

Abstract:

BACKGROUND:Unlike other anti-tumor necrosis factor alpha antibodies, golimumab does not deliver on its promise of effectiveness for treating patients with ulcerative colitis. We investigated the value of therapeutic drug monitoring for optimizing golimumab therapy. METHODS:We analyzed the golimumab pharmacokinetics data of 56 patients with moderate to severe ulcerative colitis. Induction and maintenance golimumab concentrations (296 venipuncture, 414 serum) were used to develop a population pharmacokinetic model. Exposure-response relationships were analyzed using the data of 40/56 patients with available endoscopy data. Receiver operating characteristic curve analysis was performed, and an exposure-response Markov model was developed, linking golimumab exposure to probabilities of transitioning between Mayo endoscopic subscore (MES) states from baseline to week (w)14. RESULTS:Golimumab pharmacokinetics was best described by a 2-compartment model with linear absorption and elimination. Antibodies to golimumab and previous biological therapy reduced golimumab exposure. Still, interindividual pharmacokinetic variability (IIVPK) remained largely unexplained. Endoscopic remission (ER; MESw14 ≤ 1) was achieved in 14/40 (35%) patients. Golimumab serum trough concentration thresholds of 7.4 mg/L (w6) and 3.2 mg/L (w14) predicted ER at w14 (positive predictive values [pv+] 83% and 91%, pv- 82% and 67%, respectively). The 3.2-mg/L target predicted 38% and 44% chances of achieving ER in patients with MESbaseline of 3 and 2, respectively. CONCLUSIONS:Personalized, model-based induction dosing aiming at here-established target concentrations may account for IIVPK and thus provide patients with more equal chances of achieving ER. As <50% of patients attained the exposure targets, higher golimumab induction dosing requires investigation to secure its future in clinical practice.

journal_name

Inflamm Bowel Dis

authors

Dreesen E,Kantasiripitak W,Detrez I,Stefanović S,Vermeire S,Ferrante M,Bouillon T,Drobne D,Gils A

doi

10.1093/ibd/izz144

subject

Has Abstract

pub_date

2020-03-04 00:00:00

pages

570-580

issue

4

eissn

1078-0998

issn

1536-4844

pii

5542810

journal_volume

26

pub_type

杂志文章
  • Elevated IL-13Ralpha2 in intestinal epithelial cells from ulcerative colitis or colorectal cancer initiates MAPK pathway.

    abstract:BACKGROUND:Chronic inflammation in ulcerative colitis (UC) is a sizeable risk factor for colorectal cancer (CRC). Interleukin-13 (IL-13) is elevated in the UC mucosa and may induce dysregulated signaling in neighboring intestinal epithelial cells (IECs) and thus function as a tumorogenic cytokine. METHODS:Expression o...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,收录出版

    doi:10.1002/ibd.21133

    authors: Mandal D,Levine AD

    更新日期:2010-05-01 00:00:00

  • Phylogenetic analysis of inflammatory bowel disease associated Escherichia coli and the fimH virulence determinant.

    abstract:BACKGROUND:Evidence supports the role of adherent invasive Escherichia coli (AIEC) in the pathogenesis of inflammatory bowel disease (IBD). However, little is known about the phylogenetic structure and origin of this group of bacteria. Multi-locus sequence typing (MLST), and fimH sequence analysis were performed to elu...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.20966

    authors: Sepehri S,Kotlowski R,Bernstein CN,Krause DO

    更新日期:2009-11-01 00:00:00

  • Long-term safety and tolerability of once-daily mesalamine granules in the maintenance of remission of ulcerative colitis.

    abstract:BACKGROUND:Ulcerative colitis (UC), a chronic, relapsing, and remitting inflammatory bowel disease, requires long-term treatment to maintain remission. In this study, the long-term safety and tolerability of mesalamine granules (MG) therapy was evaluated in the maintenance of UC remission. Previous prospective studies ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,多中心研究

    doi:10.1097/MIB.0000000000000076

    authors: Lichtenstein GR,Barrett AC,Bortey E,Paterson C,Forbes WP

    更新日期:2014-08-01 00:00:00

  • Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab.

    abstract:BACKGROUND:The aim of this study was to assess the clinical benefit and tolerability of adalimumab, a fully human monoclonal antibody to tumor necrosis factor (TNF), in patients with ulcerative colitis (UC). METHODS:Patients with active UC, including those who had lost response or developed intolerance to the chimeric...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.20924

    authors: Afif W,Leighton JA,Hanauer SB,Loftus EV Jr,Faubion WA,Pardi DS,Tremaine WJ,Kane SV,Bruining DH,Cohen RD,Rubin DT,Hanson KA,Sandborn WJ

    更新日期:2009-09-01 00:00:00

  • Extraintestinal manifestations and complications in inflammatory bowel disease: from shared genetics to shared biological pathways.

    abstract:BACKGROUND:The clinical presentation of the inflammatory bowel diseases (IBD) is extremely heterogenous and is characterized by various extraintestinal manifestations and complications (EIM). Increasing genetic insight for IBD and EIM shows multiple shared susceptibility loci. We hypothesize that, next to these overlap...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1097/MIB.0000000000000032

    authors: van Sommeren S,Janse M,Karjalainen J,Fehrmann R,Franke L,Fu J,Weersma RK

    更新日期:2014-06-01 00:00:00

  • Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis.

    abstract:BACKGROUND:Activation of cannabinoid (CB)(1) receptors results in attenuation of experimental colitis. Our aim was to examine the role of CB(2) receptors in experimental colitis using agonists (JWH133, AM1241) and an antagonist (AM630) in trinitrobenzene sulfonic acid (TNBS)-induced colitis in wildtype and CB(2) recept...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.20960

    authors: Storr MA,Keenan CM,Zhang H,Patel KD,Makriyannis A,Sharkey KA

    更新日期:2009-11-01 00:00:00

  • The INSPIRE study: are different personality traits related to disease-specific quality of life (IBDQ) in distressed patients with ulcerative colitis and Crohn's disease?

    abstract:BACKGROUND:To explore the relationship between personality and disease-specific quality of life [Inflammatory Bowel Disease Questionnaire (IBDQ)] in distressed [Perceived Stress Questionnaire (PSQ)] patients with ulcerative colitis (UC) and Crohn's disease (CD). METHODS:Included in the study were 56 patients with UC a...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,多中心研究

    doi:10.1002/ibd.20367

    authors: Boye B,Jahnsen J,Mokleby K,Leganger S,Jantschek G,Jantschek I,Kunzendorf S,Benninghoven D,Wilhelmsen I,Sharpe M,Blomhoff S,Malt UF,Lundin KE

    更新日期:2008-05-01 00:00:00

  • Effect of 2 psychotherapies on depression and disease activity in pediatric Crohn's disease.

    abstract:BACKGROUND:Crohn's disease (CD) is associated with depression. It is unclear if psychosocial interventions offer benefit for depressive symptoms during active CD. In this secondary analysis of a larger study of treating depression in pediatric inflammatory bowel disease, we assessed whether cognitive behavioral therapy...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/MIB.0000000000000358

    authors: Szigethy E,Youk AO,Gonzalez-Heydrich J,Bujoreanu SI,Weisz J,Fairclough D,Ducharme P,Jones N,Lotrich F,Keljo D,Srinath A,Bousvaros A,Kupfer D,DeMaso DR

    更新日期:2015-06-01 00:00:00

  • Use of Complementary and Alternative Medicine for Inflammatory Bowel Disease Is Associated with Worse Adherence to Conventional Therapy: The COMPLIANT Study.

    abstract:BACKGROUND:Complementary and alternative medicine (CAM) use is highly prevalent among inflammatory bowel disease (IBD patients). We assessed whether its use, both for IBD and for general health, influenced adherence to conventional medications. METHODS:We enrolled 392 IBD subjects in a prospective cohort study and cat...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000773

    authors: Nguyen GC,Croitoru K,Silverberg MS,Steinhart AH,Weizman AV

    更新日期:2016-06-01 00:00:00

  • Higher levels of knowledge reduce health care costs in patients with inflammatory bowel disease.

    abstract:BACKGROUND:The potentially high costs of care associated with inflammatory bowel disease are recognized. A knowledge-based self-management approach seems to reduce health care costs, improve disease control, and reduce indirect costs. The aim of this study was to determine whether there is a significant association bet...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000304

    authors: Colombara F,Martinato M,Girardin G,Gregori D

    更新日期:2015-03-01 00:00:00

  • Retinoic acid contributes to the induction of IL-12-hypoproducing dendritic cells.

    abstract:BACKGROUND:Vitamin A is an important regulator of the human immune system, especially in the gut. Recent studies have revealed that retinoic acid (RA) in gut-associated dendritic cells (DCs) enhances the transforming growth factor (TGF)-beta-dependent conversion of naïve T cells into regulatory T (Treg) cells. Thus, RA...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.20934

    authors: Wada Y,Hisamatsu T,Kamada N,Okamoto S,Hibi T

    更新日期:2009-10-01 00:00:00

  • Cost-effectiveness and Clinical Outcomes of Early Anti-Tumor Necrosis Factor-α Intervention in Pediatric Crohn's Disease.

    abstract:BACKGROUND:Anti-tumor necrosis factor-α (anti-TNF-α) treatments are increasingly used to treat pediatric Crohn's disease, even without a prior trial of immunomodulators, but the cost-effectiveness of such treatment algorithms has not been formally examined. Drug plan decision-makers require evidence of cost-effectivene...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izz267

    authors: Bashir NS,Walters TD,Griffiths AM,Ito S,Ungar WJ

    更新日期:2020-07-17 00:00:00

  • Comparative analysis of the effects of anti-IL-6 receptor mAb and anti-TNF mAb treatment on CD4+ T-cell responses in murine colitis.

    abstract:BACKGROUND:The efficacy of anti-tumor necrosis factor monoclonal antibody (anti-TNF mAb) for Crohn's disease (CD) is well established, and anti-interleukin-6 receptor (anti-IL-6R) mAb has also been reported to be effective in CD. It is, however, unclear if the efficacy and mechanisms of both agents are different in CD ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.21384

    authors: Terabe F,Fujimoto M,Serada S,Shinzaki S,Iijima H,Tsujii M,Hayashi N,Nomura S,Kawahata H,Jang MH,Miyasaka M,Mihara M,Ohsugi Y,Kishimoto T,Naka T

    更新日期:2011-02-01 00:00:00

  • Differentiation Between Pediatric Irritable Bowel Syndrome and Inflammatory Bowel Disease Based on Fecal Scent: Proof of Principle Study.

    abstract:Background:The diagnostic work-up of pediatric irritable bowel syndrome (IBS) and functional abdominal pain-not otherwise specified (FAP-NOS) commonly includes invasive tests for discrimination from inflammatory bowel disease (IBD). As this carries a high burden on patients, an ongoing need exists for development of no...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izy151

    authors: Bosch S,van Gaal N,Zuurbier RP,Covington JA,Wicaksono AN,Biezeveld MH,Benninga MA,Mulder CJ,de Boer NKH,de Meij TGJ

    更新日期:2018-10-12 00:00:00

  • Transcutaneous posterior tibial nerve stimulation for fecal incontinence in inflammatory bowel disease patients: a therapeutic option?

    abstract:BACKGROUND:Fecal incontinence associated with inflammatory bowel disease (IBD) may be particularly difficult to treat. Two recent studies showed that transcutaneous posterior tibial nerve stimulation may improve fecal continence. In this pilot study, we tested the usefulness of this noninvasive technique to treat fecal...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.20774

    authors: Vitton V,Damon H,Roman S,Nancey S,Flourié B,Mion F

    更新日期:2009-03-01 00:00:00

  • Recommendations for Quality Colonoscopy Reporting for Patients with Inflammatory Bowel Disease: Results from a RAND Appropriateness Panel.

    abstract:BACKGROUND:Consensus on what constitutes a quality colonoscopy report for patients with inflammatory bowel disease (IBD) is lacking. We developed a template for quality colonoscopy reporting that can be used broadly by endoscopists. METHODS:After a literature review of topics relevant to colonoscopy reporting, members...

    journal_title:Inflammatory bowel diseases

    pub_type: 共识发展会议,杂志文章

    doi:10.1097/MIB.0000000000000764

    authors: Devlin SM,Melmed GY,Irving PM,Rubin DT,Kornbluth A,Kozuch PL,Raffals LE,Velayos FS,Sparrow MP,Baidoo L,Bressler B,Cheifetz AS,Jones J,Kaplan GG,Siegel CA

    更新日期:2016-06-01 00:00:00

  • Patient-reported Anxiety: A Possible Predictor of Pediatric Inflammatory Bowel Disease Health Care Use.

    abstract:BACKGROUND:Anxiety is linked with adverse health-related outcomes and increased health-seeking behaviors among patients with chronic illness. Yet, this relationship has received little attention in pediatric inflammatory bowel disease. The aim of this study was to examine whether anxiety symptoms predicted youth at inc...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000864

    authors: Reigada LC,Satpute A,Hoogendoorn CJ,Cohen BH,Lai J,Bao R,Dubinsky MC,Benkov KJ

    更新日期:2016-09-01 00:00:00

  • Increased strength of erythrocyte aggregates in blood of patients with inflammatory bowel disease.

    abstract:BACKGROUND:Increased strength of red blood cell (RBC) aggregates are present during the acute inflammatory response and contribute to erythrocyte aggregation and may lead to microvascular dysfunction. Inflammatory bowel diseases (IBDs) are characterized by damage to the bowel wall. This damage may be at least partially...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.20838

    authors: Maharshak N,Arbel Y,Shapira I,Berliner S,Ben-Ami R,Yedgar S,Barshtein G,Dotan I

    更新日期:2009-05-01 00:00:00

  • Factors Affecting Clinical and Endoscopic Outcomes of Placebo Arm in Trials of Biologics and Small Molecule Drugs in Ulcerative Colitis: A Meta-Analysis.

    abstract:BACKGROUND:Previous systematic cumulative analyses of the placebo arm in ulcerative colitis (UC) were limited by the wide heterogeneity in the scores and definitions of response. We aimed at estimating the placebo rates of remission, response, and mucosal healing (MH) in phase 2 and 3 randomized placebo-controlled tria...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,meta分析

    doi:10.1093/ibd/izy365

    authors: Macaluso FS,Maida M,Ventimiglia M,Renna S,Cottone M,Orlando A

    更新日期:2019-05-04 00:00:00

  • Length and type of recurrent ileitis after ileal resection correlate with presurgical features in Crohn's disease.

    abstract:SUMMARY:: Crohn's disease of the terminal ileum usually recurs after an ileocolonic resection. To compare the length and the disease behavior of recurrent ileitis with the presurgical disease characteristics, we studied 31 consecutive patients who had recurrent Crohn's disease symptoms and who had undergone an ileoceca...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:

    authors: Dʼhaens G,Baert F,Gasparaitis A,Hanauer S

    更新日期:1997-01-01 00:00:00

  • Fatal staphylococcal sepsis in Crohn's disease after infliximab.

    abstract::We report a case of a 40-year-old woman who had received infliximab for perianal Crohn's disease. After six infusions of infliximab, the patient developed staphylococcal pneumonia resulting in fatal adult respiratory distress syndrome. The case is discussed in the context of the toxicity profile of infliximab. ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/00054725-200409000-00024

    authors: Herrlinger KR,Borutta A,Meinhardt G,Stange EF,Fellermann K

    更新日期:2004-09-01 00:00:00

  • Chemoprophylaxis of colorectal cancer in inflammatory bowel disease: current concepts.

    abstract::Ulcerative colitis and Crohn's disease both confer an increased risk of developing colorectal cancer. The use of 5-aminosalicylate as a remission-inducing agent has been long accepted. Its use as a potential chemoprophylactic agent has been proposed and is used by some practitioners. This review examines the most rece...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1002/ibd.20186

    authors: Levine JS,Burakoff R

    更新日期:2007-10-01 00:00:00

  • Comparison of Fecal Inflammatory Markers in Crohn's Disease.

    abstract:BACKGROUND:Fecal biomarkers are used increasingly to monitor Crohn's disease (CD). However, the relative accuracy of different markers in identifying inflammation has been poorly evaluated. We evaluated fecal calprotectin (FC), lactoferrin (FL), and S100A12 (FS) using endoscopic validation in a prospective study of the...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/MIB.0000000000000671

    authors: Wright EK,Kamm MA,De Cruz P,Hamilton AL,Ritchie KJ,Keenan JI,Leach S,Burgess L,Aitchison A,Gorelik A,Liew D,Day AS,Gearry RB

    更新日期:2016-05-01 00:00:00

  • Quality of life rapidly improves with budesonide therapy for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group.

    abstract::Our aims were to assess the impact on health-related quality of life (HRQOL) of a controlled ileal release (CIR) formulation of budesonide in active Crohn's disease (CD) and further define the role of HRQOL, using the Inflammatory Bowel Disease Questionnaire (IBDQ), in assessing outcome in CD. A randomized trial was c...

    journal_title:Inflammatory bowel diseases

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00054725-200008000-00004

    authors: Irvine EJ,Greenberg GR,Feagan BG,Martin F,Sutherland LR,Thomson AB,Nilsson LG,Persson T

    更新日期:2000-08-01 00:00:00

  • Bile acid malabsorption deactivates pregnane X receptor in patients with Crohn's disease.

    abstract:BACKGROUND:Recent studies have suggested that the downregulation of pregnane X receptor (PXR) may contribute to the susceptibility and exacerbation of Crohn's disease (CD). Because bile acid malabsorption is one of the features of CD and bile acids are potential activators of PXR, we explored the relationship between b...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0b013e318281f423

    authors: Iwamoto J,Saito Y,Honda A,Miyazaki T,Ikegami T,Matsuzaki Y

    更新日期:2013-05-01 00:00:00

  • Homing imprinting and immunomodulation in the gut: role of dendritic cells and retinoids.

    abstract::Lymphocyte migration is at the heart of chronic inflammatory ailments, including inflammatory bowel disease (IBD). Whereas naïve lymphocytes migrate to all secondary lymphoid organs, they are mostly excluded from nonlymphoid peripheral tissues. Upon activation, lymphocytes change their pattern of adhesion receptors an...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1002/ibd.20280

    authors: Mora JR

    更新日期:2008-02-01 00:00:00

  • Oral mesalazine (5-ASA) treatment may protect against proximal extension of mucosal inflammation in ulcerative proctitis.

    abstract:OBJECTIVES:Studies aimed at establishing which characteristics of patients with ulcerative proctitis could be predictive of the extension of inflammation have failed to provide conclusive results. The aim of the study was to evaluate the prognostic role of clinical and therapeutic parameters in patients with proctitis....

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/00054725-200411000-00006

    authors: Pica R,Paoluzi OA,Iacopini F,Marcheggiano A,Crispino P,Rivera M,Bella A,Consolazio A,Paoluzi P

    更新日期:2004-11-01 00:00:00

  • Phenotype classification in IBD: Is there an impact on therapy?

    abstract::This review summarizes the current phenotypic classifications of inflammatory bowel disease (IBD) and outlines their implications for diagnosis, therapy, prognosis, clinical trial design, and genotype-phenotype correlations. ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.20232

    authors: Walfish A,Sachar D

    更新日期:2007-12-01 00:00:00

  • Inflammatory bowel disease associates with proinflammatory potential of the immunoglobulin G glycome.

    abstract:BACKGROUND:Glycobiology is an underexplored research area in inflammatory bowel disease (IBD), and glycans are relevant to many etiological mechanisms described in IBD. Alterations in N-glycans attached to the immunoglobulin G (IgG) Fc fragment can affect molecular structure and immunological function. Recent genome-wi...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000372

    authors: Trbojević Akmačić I,Ventham NT,Theodoratou E,Vučković F,Kennedy NA,Krištić J,Nimmo ER,Kalla R,Drummond H,Štambuk J,Dunlop MG,Novokmet M,Aulchenko Y,Gornik O,Campbell H,Pučić Baković M,Satsangi J,Lauc G,IBD-BIOM Consor

    更新日期:2015-06-01 00:00:00

  • Comparison of QD and TID oral mesalazine for maintenance of remission in quiescent ulcerative colitis: a double-blind, double-dummy, randomized multicenter study.

    abstract:BACKGROUND:Mesalazine preparations are widely used to treat mild to moderately severe ulcerative colitis (UC). We compared once-daily administration of oral mesalazine in patients with quiescent UC with the established 3-times-daily prescription, assessing the efficacy and safety of each method in maintaining remission...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/MIB.0b013e318286fa3d

    authors: Watanabe M,Hanai H,Nishino H,Yokoyama T,Terada T,Suzuki Y

    更新日期:2013-07-01 00:00:00